Find Clinical Trial

A randomised, open-label, multi-centre, two-arm Phase 3 study comparing futuximab/modotuximab in combination with trifluridine/tipiracil to trifluridine/tipiracil single agent with a Safety Lead-In part in participants with KRAS/NRAS and BRAF wild type metastatic colorectal cancer previously treated with standard treatment and anti-EGFR therapy


← Back
Study Phase

Phase 3

Therapeutic Area

Cancers

IndicationMetastatic Colorectal Cancers
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

Futuximab, Modotuximab,
S095026

Active Substance CodeS095026
Protocol CodeCL3-95026-001
EudraCT Code2021-003151-41
NCT CodeNCT05223673


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility